Blue Earth touts Axumin results in Lancet

By AuntMinnieEurope.com staff writers

May 28, 2021 -- Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting results of a study published in Lancet showing that postprostatectomy radiation therapy guided by the company's PET radiotracer Axumin (fluciclovine F-18) helped increase biochemical event-free survival rates in men with recurrent prostate cancer.

Of 165 patients whose prostate cancer returned following surgical removal of their prostate, the researchers found that 75.5% of those whose treatment was integrated Axumin PET imaging were event-free after three years, compared with 63% for whom only conventional imaging techniques were used to plan treatment, according to the company.

The study was published on 7 May and was led by researchers at the Winship Cancer Institute of Emory University in Atlanta.


Copyright © 2021 AuntMinnieEurope.com
 

To read this and get access to all of the exclusive content on AuntMinnieEurope.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnieEurope.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: